BVS is the ticker symbol for Bioventus Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks BVS with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is BVS a good stock to buy?

13F Pro's AI ranking engine scores BVS at 59.9/100, ranked #902 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for BVS is available at https://13fpro.ai/company/BVS. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source BVS data?

All Bioventus Inc. fundamentals and ownership data come directly from SEC EDGAR. Bioventus Inc. files with the SEC under CIK 1665988. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Bioventus Inc. BVS

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #902 of 2,925TOP 50%

Why it scores 60 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$153.21M

Quarter to Jun 27

Net income

$33.44M

Quarter to Jun 27

Free cash flow

$18.91M

Quarter to Jun 27

Operating margin

12.5%

Quarter to Jun 27

Top Institutional Holders

as of Q2 2026

$509.38M total

Essex Woodlands Management, Inc.

$122.92M0.0%

Juniper Investment Company, LLC

$65.51M0.0%

Nantahala Capital Management, LLC

$56.64M-2.0%

BlackRock, Inc.

$32.44M+9.6%

ROYCE & ASSOCIATES LP

$17.31M+18.9%

VANGUARD CAPITAL MANAGEMENT LLC

$16.54M+2.2%

GEODE CAPITAL MANAGEMENT, LLC

$12.89M+16.9%

AMERICAN CENTURY COMPANIES INC

$12.78M+118.4%

DIMENSIONAL FUND ADVISORS LP

$10.65M+29.2%

STATE STREET CORP

$10.43M+11.8%

VANGUARD PORTFOLIO MANAGEMENT LLC

$9.84M+7.2%

Hillsdale Investment Management Inc.

$8.57M+35.3%

Engine Capital Management, LP

$8.50M+185.9%

WELLINGTON MANAGEMENT GROUP LLP

$7.06M+385.5%

RENAISSANCE TECHNOLOGIES LLC

$6.95M+50.4%

OBERWEIS ASSET MANAGEMENT INC/

$6.70M+13.0%

GOLDMAN SACHS GROUP INC

$6.16M+37.8%

KENNEDY CAPITAL MANAGEMENT LLC

$4.40M-1.8%

FMR LLC

$4.27M+14.3%

NORTHERN TRUST CORP

$4.19M+22.3%

PRUDENTIAL FINANCIAL INC

$3.72M+103.6%

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

$3.70M+4.8%

TOCQUEVILLE ASSET MANAGEMENT L.P.

$3.49M+7.2%

ACADIAN ASSET MANAGEMENT LLC

$3.18M+1.2%

VANGUARD FIDUCIARY TRUST CO

$3.09M+2.1%

See all 157 institutional holders →

What's Driving BVS's Business? Latest 10-Q Breakdown

25/25 datapoints verified

AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 27, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue $153.2M (+3.8% YoY) driven by Pain Treatments growth; $24.6M tax benefit from valuation allowance release more than doubled net income to $36.2M.

Biggest Revenue Drivers

U.S. Pain Treatments$72.7M+12.8% YoY

9.3% volume growth led by Durolane plus 3.6% price growth from favorable rebates and customer mix.

U.S. Surgical Solutions$43.6M-4.7% YoY

Lower Ultrasonics volumes offset growth in other categories.

Biggest Revenue Drivers

Total revenue: $153.2M+3.8% YoY

U.S. Pain Treatments$72.7M+12.8% YoY

9.3% volume growth led by Durolane plus 3.6% price growth from favorable rebates and customer mix.

U.S. Surgical Solutions$43.6M-4.7% YoY

Lower Ultrasonics volumes offset growth in other categories.

U.S. Restorative Therapies$18.2M-2.2% YoY

Unfavorable customer mix for EXOGEN Bone Stimulation System.

International$18.7M-0.8% YoY

Essentially flat; Pain Treatments growth offset by declines in Surgical Solutions and Restorative Therapies.

Largest Expense Items

Selling, general and administrative$82.7M+4.6% YoY

Higher professional service costs including legal-related expenses, increased stock-based compensation, and higher sales commissions.

Cost of sales (including depreciation and amortization)$47.5M+4.3% YoY

Higher freight, manufacturing variances, and unfavorable EXOGEN ASP, partially offset by lower depreciation.

Research and development$3.2MFlat YoY

Consulting expenses offset by compensation-related cost increases.

Margins: Gross margin declined 10 basis points to 69.0% due to freight headwinds (40bps), lower EXOGEN ASP (30bps), and scrap/manufacturing charges (20bps), partially offset by 70bps benefit from lower depreciation. Operating margin improved to 12.5% from 12.4% YoY despite SG&A deleveraging.

Watch Items from the Filing

One customer represents 13.3% of Q2 revenue ($20.4M) and 27.7% of accounts receivable; customer concentration risk on rebate volatility and payment timing.
Rebate estimate changes on U.S. HA products represented 2.8% of U.S. segment revenue in Q2 2026 vs. 2.1% in Q2 2025; increased volatility from third-party billing process changes.
Board conducting strategic alternatives review following unsolicited acquisition proposal; process could distract management, result in litigation costs, and adversely affect employee retention and business operations.
Multiple shareholder derivative lawsuits consolidated; two settlement-in-principle reached July 17, 2026 limited to corporate governance reforms with no material attorney fee awards expected.
Discretionary debt prepayments of $42M in first half 2026 reduce interest burden; outstanding term loan $248.5M vs. $296.3M at year-end 2025; leverage ratio improving.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Debt/Equity

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/BVS

Earnings Per Share

13fpro.ai/company/BVS

Loading ratio trend…

About Bioventus Inc. (BVS): stock profile, AI score and financials

Bioventus Inc. (BVS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BVS at 59.9/100 on a composite quality score built from its SEC filings, placing it at rank #902 of 2,925 stocks — the top half of the AI-ranked universe. BVS scores in the top quartile across earnings quality (80.5), balance sheet strength (80.2), institutional flow (78.3). Areas of concern include revenue scale (39.4) and revenue growth (39.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 37.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Bioventus Inc. reports quarterly revenue of $153.2M, net income of $33.4M, an operating margin of 12.5%. Top institutional holders of BVS by reported 13-F value include Essex Woodlands Management, Juniper Investment Company, Nantahala Capital Management, based on the most recent SEC filings. BVS trades on the Nasdaq exchange and files with the SEC under CIK 1665988. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BVS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bioventus Inc. directly from SEC EDGAR.

Financials through the period ended Jun 27, 2026SEC EDGAR: CIK 1665988 →

Bioventus Inc. BVS

Top Institutional Holders

What's Driving BVS's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

Companies similar to BVS

BVS insiders

About Bioventus Inc. (BVS): stock profile, AI score and financials